PUBLIC COMPANY
saveNEUROCRINE
USupdated 5mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
- phase4A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- phase3NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
🐶 Hiring Signal
News
- Moderna, Neurocrine bring back familiar faces; Pharming CEO exits after clashing with board→ Juan Andres will come out of retirement to rejoin Moderna as COO on Oct. 5, bringing his intimate knowledge of the company as its Merck-partnered cancer vaccine gathers momentum in the clinic. An…endpoints · 4d ago
- Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEOEric Cantor, who represented Virginia in the U.S. House of Representatives for 14 years and served as House majority leader from 2011 to 2014, will step up as PhRMA’s next president and CEO on Nov.…fiercebiotech · 4d ago
- An AI drug specialist zeroes in on rare forms of obesitySuperluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selectively than — Rhythm Pharmaceuticals’ marketed med…biopharma_dive · 1mo ago
- STAT+: Abivax has still not been acquired. What’s going on?Biotech M&A activity is off the charts, yet the French drugmaker Abivax hasn't been picked up yet. There may be some explanations.stat · 1mo ago
- STAT+: Alnylam’s heart drug troubles take center stage at a cardiology conferenceThe European Society of Cardiology Congress that kicks off Friday in Munich will be a consequential meeting for Alnylam Pharmaceuticals.stat · 1mo ago
- STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejectionCapricor Therapeutics is trying to stave off FDA rejection of its cell therapy for Duchenne muscular dystrophy.stat · 1mo ago
- STAT+: One of the most consequential years for cancer treatment, everBetween success with a pancreatic cancer drug and now success with an mRNA neoantigen vaccine, it has been a banner year for developing cancer therapies.stat · 1mo ago
- Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, moreAmylyx shares good news for its investigational GLP-1 blocker; Definium announces positive data for its LSD-based therapy in anxiety; Summit/Akeso’s ivonescimab shows degrading survival benefits; p…biospace · 1mo ago
- STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promiseEyepoint said patients given its experimental treatment for wet AMD failed to maintain vision with less frequent injections compared to a standard treatment.stat · 1mo ago
- STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefitEurope pulls Tavneos over trial integrity concerns, pricing concerns over AstraZeneca's hypertension drug, and more biotech news from The Readoutstat · 1mo ago
comments(0)
5-min edit window · permanent after that